| Autor: |
Chu, Xin-Jie, DePinto, Wanda, Bartkovitz, David, So, Sung-Sau, T. Vu, Binh, Packman, Kathryn, Lukacs, Christine, Ding, Qingjie, Jiang, Nan, Wang, Ka, Goelzer, Petra, Yin, Xuefeng, A. Smith, Melissa, X. Higgins, Brian, Chen, Yingsi, Xiang, Qing, Moliterni, John, Kaplan, Gerald, Graves, Bradford, Lovey, Allen, Fotouhi, Nader |
| Zdroj: |
Journal of Medicinal Chemistry; November 2006, Vol. 49 Issue: 22 p6549-6560, 12p |
| Abstrakt: |
The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. Since deregulation of CDKs is found with high frequency in many human cancer cells, pharmacological inhibition of CDKs with small molecules has the potential to provide an effective strategy for the treatment of cancer. The 2,4-diamino-5-ketopyrimidines 6reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family. This diaminopyrimidine core with a substituted 4-piperidine moiety on the C2-amino position and 2-methoxybenzoyl at the C5 position has been identified as the critical structure responsible for the CDK inhibitory activity. Further optimization has led to a good number of analogues that show potent inhibitory activities against CDK1, CDK2, and CDK4 but are inactive against a large panel of serine/threonine and tyrosine kinases (Ki> 10 M). As one of these representative analogues, compound 39 (R547) has the best CDK inhibitory activities (Ki 0.001, 0.003, and 0.001 M for CDK1, CDK2, and CDK4, respectively) and excellent in vitro cellular potency, inhibiting the growth of various human tumor cell lines including an HCT116 cell line (IC50 0.08 M). An X-ray crystal structure of 39 bound to CDK2 has been determined in this study, revealing a binding mode that is consistent with our SAR. Compound 39demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition. On the basis of its superior overall profile, 39was chosen for further evaluation and has progressed into Phase I clinical trial for the treatment of cancer. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
